Consistent with the screen result, targeting KDM2A using two newly designed sgRNAs (referred to as sgK#1 and sg#2) profoundly suppressed the growth of ALT-positive ALT#1 (Fig. 1e), osteosarcoma Saos2 (Fig. 1f), U2OS (Supplementary Fig. 2c), G292 (Supplementary Fig. 2d), rhabdomyosarcoma Hs729 (Supplementary Fig. 2e), and patient-derived pGBM6 glioblastoma cells (Supplementary Fig. 2f). This evidence concerns the gene GPT and rhabdomyosarcoma.